Targeting WEE1, a crucial regulator of the G2 checkpoint in endocrine and CDK4/6 inhibitor-resistant breast cancer cells, effectively reduces cell proliferation and induces G2/M arrest, apoptosis, and DNA double-stranded breaks, offering a promising therapeutic strategy for treatment-resistant HR+ breast cancer [61]. Here, CDK4 is linked to breast cancer.